Dose-finding PKPD Trial for RE02 in Healthy Subjects

Healthy Clinical Trial

Official title:

Double-blind, Randomized, Dose-response Study of RE02 in Healthy Subjects

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05979727
• Other study ID #: MEO-DMT-VR
• Status: Recruiting
• Phase: Phase 1
• Start date: November 20, 2023
• Est. completion date: January 2024

Study information

• Verified date: November 2023
• Source: Reconnect Labs
• Contact: Robin von Rotz
• Phone: +41797990831
• Email: robin[@]reconnect-labs.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to compare corresponding inter- and intraindividual pharmacokinetic and pharmacodynamic profiles including assessments of safety & tolerability of three different doses against a placebo control.

Description:

Participants will undergo a series of four study days with varying doses of RE02 and a placebo. The intervention is embedded in controlled environment and continuous psychological support. Pharmacokinetic and pharmacodynamic assessments are obtained over the course of 6 hours on each study visit to estimate dose-exposure relationship and drug-drug-interaction. Additionally, the occurrence of adverse events will be closely monitored throughout the whole study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 15
• Est. completion date: January 2024
• Est. primary completion date: December 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 25 Years to 45 Years

Eligibility

Inclusion Criteria:

• Willing and capable to give informed consent for the participation in the study after it has been thoroughly explained

• Willing to refrain from drinking alcohol one day before testing days and caffeinated drinks at the testing days and from consuming psychoactive substances or other medications for 2 weeks before testing days and for the duration of the study

• Already experienced with psychedelic substances (at least 5 prior experiences - microdoses do not count)

• Able and willing to comply with all study requirements

• Informed consent form was signed

• Good knowledge of the German language

• Participant informs study physicians / project scientists about simultaneous treatment or therapy with other physicians and about current intake of psychotropic substances or medication

• Women of childbearing potential are required to use effective, established contraception, such as oral, injected or implanted hormonal methods of contraception, placement of an intrauterine device (IUD) or intrauterine system (IUS), barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository

Exclusion Criteria:

• Previous significant adverse response to a hallucinogenic drug

• Participation in another study where pharmaceutical compounds will be given

• Presence of Axis I affective, anxiety, or dissociative disorders

• Present or antecedent diagnosis of bipolar disorder (I, II, not otherwise specified), schizophrenia, schizoaffective disorder, psychosis, or other disorders from the psychotic spectrum

• First-degree relatives with present or antecedent schizophrenia, schizoaffective disorder, or bipolar disorder type I

• History of head trauma, seizures, cancer, or cerebrovascular accidents

• Recent cardiac or brain surgery

• Current abuse of medication or psychotropic substances (including nicotine addiction) according to SCID I criteria

• Presence of major internal or neurological disorders (including sepsis, pheochromocytoma, thyrotoxicosis, drug-induced fibrosis, familiar or basilar artery migraine)

• Cardiovascular disease (hypertonia, coronary artery disease, heart insufficiency, myocardical infarction, coronary spastic angina)

• Peripheral vascular disease (thromboangiitis obliterans, luetic arteritis, severe arteriosclerosis, thrombophlebitis, Raynaud's disease)

• Cerebrovascular disease (e.g., stroke, intracranial bleeding / hemorrhage, intracranial aneurysm)

• Serious abnormalities in ECG or blood count/chemistry

• Liver or renal or pulmonary disease

• Current use of medications with significant interaction potential with MAOI (e.g., antidepressants, antipsychotics, psychostimulants, dopaminergic/serotonergic agents, anticonvulsants)

• high risk of adverse emotional or behavioral reaction based on investigator's clinical evaluation (e.g., evidence of serious personality disorder, serious current stressors, lack of social support)

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• RE02
Low, medium or high dose of RE02
• Manitol
Placebo Comparator

Locations

Country	Name	City	State
Switzerland	University Hospital of Psychiatry Zurich	Zürich	ZH

Sponsors (1)

Lead Sponsor	Collaborator
Reconnect Labs

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetic parameter "Cmax"	Dose-dependent changes in Cmax of several doses of RE02	Changes from baseline to study days 1,2,3,4
Primary	Pharmacokinetic parameter "Area under the curve (AUC)"	Dose-dependent changes in AUC of several doses of RE02.	Changes from baseline to study days 1,2,3,4
Primary	Pharmacokinetic parameter "T1/2"	Dose-dependent changes in T1/2 of several doses of RE02.	Changes from baseline to study days 1,2,3,4
Primary	Incidence of Treatment-Emergent Adverse Events	Dose-dependent changes in incidence of adverse drug reactions	On study days 1,2,3,4
Primary	Blood count (Lab biochemistry)	Changes from baseline in blood count	Changes from baseline to End of Study, an average of 4 weeks
Primary	Clinical chemistry (Lab biochemistry)	Changes from baseline in any clinical chemistry parameter with potential clinical relevance.	Changes from baseline to End of Study, an average of 4 weeks
Primary	Blood coagulation (Lab biochemistry)	Changes from baseline in blood coagulation	Changes from baseline to End of Study, an average of 4 weeks
Primary	QT interval (12-lead Electrocardiogram [ECG])	Dose-dependent changes of QT intervals assessed by clinical 12-lead ECG)	Changes from baseline to study days 1,2,3,4
Primary	Blood pressure	Dose-dependent changes in systolic and diastolic blood pressure	Changes from baseline to study days 1,2,3,4
Primary	Heart rate	Dose-dependent changes in heart rate	Changes from baseline to study days 1,2,3,4
Primary	Temperature	Dose-dependent changes in temperature	Changes from baseline to study days 1,2,3,4
Primary	Subjective effects	Dose-dependent changes in trajectories of subjective effects	Changes from baseline to study days 1,2,3,4